These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 21144724

  • 1. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C, Hattersley H, Di Scala L, Drollmann A.
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [Abstract] [Full Text] [Related]

  • 2. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, Dolker M.
    Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
    [Abstract] [Full Text] [Related]

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 4. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK.
    Pulm Pharmacol Ther; 2010 Oct; 23(5):438-44. PubMed ID: 20416390
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T.
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [Abstract] [Full Text] [Related]

  • 7. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B, Dhembare P, Jantikar A, Mahadik P, Gokhale P, Gogtay JA, Salvi SS.
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
    Bateman E, Feldman G, Kilbride S, Brooks J, Mehta R, Harris S, Maden C, Crater G.
    Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
    [Abstract] [Full Text] [Related]

  • 9. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG.
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [Abstract] [Full Text] [Related]

  • 10. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.
    Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D.
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R, Chapman KR, Rudolf M, Mehta R, Kho P, Alagappan VK, Chen H, Banerji D.
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [Abstract] [Full Text] [Related]

  • 18. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.